FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/06/2024
Voltar para busca
Dado oficial do USPTO
CELLAÏON
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
34
Atualização mais recente
06/06/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
16/06/2022
Data de registro
05/03/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
05/03/2024
Última transação
05/03/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
BE
Examinador
EINSTEIN, MATTHEW
Unidade examinadora
M60
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Cellaïon, société anonyme
Representantes
Clifford D Hyra Fresh IP PLC
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Cells originating from human tissuefor medicalclinical or veterinary useliver derived cells and stem cells or liver progenitor cells; pharmaceutical preparations in the field of liver derived cells and stem cells or liver progenitor cells for the treatment of diseases that require cell therapy medicinal productsliver diseaseschronic biliary diseasescholestatic diseasesage-related diseasesbone and cartilage disorderspancreatic diseaseskidney diseasespulmonary diseasescardiovascular diseaseseye diseasesocular diseasesorgan injuryorgan failureblood coagulation disordersClarkson diseasediabetesskin diseasescancermetabolic diseasesinflammatory diseasesinflammationneurodegenerative diseasesfibrotic diseasesproliferative diseasesinfectious diseasesautoimmune diseasesdiseases with unwanted immune responsesepsissepsis induced diseasescellular senescence; surgical implants comprised of living tissue grown from stem cells or progenitor cells in the field of liver derived cells and stem cells or liver progenitor cells; transplants being living tissue in the form of liver derived cells and stem cells or liver progenitor cells; live organs and tissues for surgical purpose in the field of liver derived cells and stem cells or liver progenitor cells; surgical implants comprising living tissue grown from stem cells or progenitor cells in the field of liver derived cells and stem cells or liver progenitor cells; cell-based pharmaceutical preparations in the field of liver derived cells and stem cells or liver progenitor cells for the treatment of liver diseaseschronic biliary diseasescholestatic diseasesage-related diseasesbone and cartilage disorderspancreatic diseaseskidney diseasespulmonary diseasescardiovascular diseaseseye diseasesocular diseasesorgan injuryorgan failureblood coagulation disordersClarkson diseasediabetesskin diseasescancermetabolic diseasesinflammatory diseasesinflammationneurodegenerative diseasesfibrotic diseasesproliferative diseasesinfectious diseasesautoimmune diseasesdiseases with unwanted immune responsesepsissepsis induced diseasescellular senescence
Classe 42
Biomedical research and development services in relation to the testing of biological samples to determine the presence and activity of stem cellsprogenitor cells and liver cellsin particularliver stem cells and liver progenitor cells
Publicações
Histórico de despachos e eventos da marca no USPTO.
34 publicações encontradas
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
11/03/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/03/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
05/03/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
21/02/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
21/02/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
21/12/2023
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
21/12/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
21/12/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
21/12/2023
GPNX
NOTIFICATION PROCESSED BY IB
19/12/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
19/12/2023
PUBO
PUBLISHED FOR OPPOSITION
19/12/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
29/11/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
29/11/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
29/11/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
16/11/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/10/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/10/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
20/10/2023
RFNT
REFUSAL PROCESSED BY IB
26/06/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/06/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/06/2023
RFRR
REFUSAL PROCESSED BY MPU
03/06/2023
LIME
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
23/05/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/04/2023
CNRT
NON-FINAL ACTION WRITTEN
05/04/2023
DOCK
ASSIGNED TO EXAMINER
29/03/2023
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
19/03/2023
CORR
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
01/12/2022
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
19/09/2022
MAFR
APPLICATION FILING RECEIPT MAILED
16/08/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/08/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/08/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CELLAÏON ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.